An Extension Study of the Safety and Anti-leukemic Effects of Imatinib Mesylate in Patients (Male or Female ≥18 Years) With Ph + CML in Blast Crisis

Update l'année dernière
Reference: NCT00171158

Woman and Man


This extension II study will allow for further follow-up of the disease under treatment with imatinib mesylate and allow the patients to continue to receive imatinib mesylate.

Inclusion criteria

  • Philadelphia Positive Chronic Myeloid Leukemia in Myeloid Blast Crisis